Data Sharing, Clinical Trials, and Biomarkers in Precision Oncology: Challenges, Opportunities, and Programs at the Department of Veterans Affairs

Cancer genomic research reveals that a similar cancer clinical phenotype (e.g., non‐small cell lung cancer) can arise from various mutations in tumor DNA. Thus, organ of origin is not a definitive classification. Further, targeted therapy for cancer patients (precision oncology) capitalizes on knowl...

Full description

Saved in:
Bibliographic Details
Published inClinical pharmacology and therapeutics Vol. 101; no. 5; pp. 586 - 589
Main Authors Fiore, LD, Brophy, MT, Ferguson, RE, Shannon, C, Turek, SJ, Pierce‐Murray, K, Ajjarapu, S, Huang, GD, Lee, CSE, Lavori, PW
Format Journal Article
LanguageEnglish
Published United States 01.05.2017
Subjects
Biomarkers, Tumor
Clinical Trials as Topic - legislation & jurisprudence
Clinical Trials as Topic - statistics & numerical data
DNA, Neoplasm - genetics
Genomics
Humans
Information Dissemination - legislation & jurisprudence
Medical Oncology - legislation & jurisprudence
Medical Oncology - statistics & numerical data
Precision Medicine - trends
United States
United States Department of Veterans Affairs
Online AccessGet full text

Cover

More Information
Summary:Cancer genomic research reveals that a similar cancer clinical phenotype (e.g., non‐small cell lung cancer) can arise from various mutations in tumor DNA. Thus, organ of origin is not a definitive classification. Further, targeted therapy for cancer patients (precision oncology) capitalizes on knowledge of individual patient mutational status to deliver treatment directed against the protein products of these mutations with the goal of reducing toxicity and enhancing efficacy relative to traditional nontargeted chemotherapy.
ISSN:0009-9236
1532-6535
DOI:10.1002/cpt.660